文献速递泌尿男性生殖肿瘤

Custirsen联合卡巴他赛与泼尼松治疗多西他赛经治转移性去势抵抗性前列腺癌的III期AFFINITY试验

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2017-10-09

AFFINITY是一项随机、开放标签、国际III期试验,纳入635例多西他赛经治的转移性去势抵抗性前列腺癌患者,比较卡巴他赛+泼尼松联合或不联合custirsen。研究未观察到生存获益,卡巴他赛+泼尼松仍为标准治疗。

要点

  • 卡巴他赛+泼尼松仍是多西他赛经治mCRPC患者的标准治疗。

核心结论

  • 在多西他赛经治的转移性去势抵抗性前列腺癌患者中,卡巴他赛+泼尼松联合custirsen未观察到生存获益。
  • 卡巴他赛+泼尼松仍是多西他赛化疗后进展的转移性去势抵抗性前列腺癌患者的标准治疗。

研究设计与样本

  • 随机、开放标签、国际III期试验,从8个国家95个癌症治疗中心招募患者。
  • 纳入635例经影像学证实多西他赛治疗后进展的转移性去势抵抗性前列腺癌男性,Karnofsky体能状态>70%且适合化疗。
  • 按1:1中央随机分配至卡巴他赛+泼尼松联合custirsen组(n=317)或卡巴他赛+泼尼松组(n=318)。
  • 分层因素包括筛查时使用阿片类药物控制前列腺癌相关疼痛、影像学证实一线多西他赛治疗后进展、既往接受阿比特龙或恩扎卢胺治疗。
  • 共同主要终点为全随机人群和预后不良亚组的总生存期;除安全性外均采用意向性治疗分析。

主要发现

  • 联合组 vs 对照组最常见的≥3级不良事件:中性粒细胞减少70/315(22%) vs 61/312(20%),贫血68(22%) vs 49(16%),疲乏23(7%) vs 18(6%),无力16(5%) vs 8(3%),骨痛16(5%) vs 5(2%),发热性中性粒细胞减少16(5%) vs 9(3%)。
  • 严重不良事件联合组155例(49%) vs 对照组132例(42%)。
  • 联合组治疗30天内死亡27例(其中7例判定为治疗相关) vs 对照组17例(其中8例判定为治疗相关)。

关键数值与推荐

  • 联合组方案:卡巴他赛25 mg/m²静脉每21天+口服泼尼松10 mg每日,联合custirsen 640 mg静脉第1、8、15天给药并含前3次负荷剂量,直至疾病进展、不可接受毒性或完成10个治疗周期。
  • 对照组方案:卡巴他赛25 mg/m²静脉每21天+口服泼尼松10 mg每日。
  • 共同主要终点:全随机人群和预后不良亚组的总生存期。
  • 分层因素:筛查时使用阿片类药物控制前列腺癌相关疼痛、影像学证实一线多西他赛治疗后进展、既往接受阿比特龙或恩扎卢胺治疗。

临床怎么用

  • 对于多西他赛经治的转移性去势抵抗性前列腺癌患者,卡巴他赛+泼尼松联合custirsen未显示生存获益,不应在临床中为此目的联合custirsen。
  • 卡巴他赛+泼尼松仍作为多西他赛化疗后进展的转移性去势抵抗性前列腺癌患者的标准治疗。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Docetaxel and cabazitaxel improve overall survival compared with mitoxantrone in patients with metastatic castration-resistant prostate cancer. Custirsen (OGX011) is a second generation highly specific antisense oligonucleotide that inhibits the production of clusterin, an antiapoptotic protein that is upregulated in response to chemotherapy and that confers treatment resistance. We aimed to assess whether custirsen in combination with cabazitaxel and prednisone increases overall survival in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel. METHODS: In this randomised, open-label, international, phase 3 trial, men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment with a Karnofsky performance status of more than 70% and who were fit for chemotherapy, were recruited from 95 cancer treatment centres in eight countries. Patients were randomly assigned (1:1) centrally using permuted blocks (block size 8) to receive cabazitaxel plus prednisone (cabazitaxel 25 mg/m2 intravenously every 21 days plus oral prednisone 10 mg daily) with or without custirsen (640 mg intravenously on days 1, 8, and 15, plus three previous loading doses) until disease progression, unacceptable toxicity, or the completion of ten treatment cycles. Randomisation was stratified by use of opioids for prostate cancer-related pain at screening, disease progression following first-line docetaxel treatment established by radiographic evidence, and previous treatment with abiraterone or enzalutamide. The co-primary endpoints were overall survival in all randomly assigned patients and in a poor-prognosis subgroup. All analyses were intention to treat with the exception of safety, which was reported for patients who received any assigned treatment. The trial has been completed and the results presented here are the final analysis. This trial is registered with Clinicaltrials.gov, number NCT01578655. FINDINGS: Between Sept 9, 2012, and Sept 29, 2014, 795 patients were screened for enrolment. 635 men were eligible for inclusion and were randomly assigned (n=317 in the cabazitaxel and prednisone plus custirsen group and n=318 in the cabazitaxel and prednisone group). Median follow up was 28·3 months (IQR 24·4-34·5) for the custirsen group and 29·8 months (IQR 25·3-35·2) for the control group. Median overall survival in all randomly assigned patients did not differ between the two groups (14·1 months [95% CI 12·7-15·9] in the curtisen group vs 13·4 months [12·1-14·9] in the control group; hazard ratio [HR] 0·95 [95% CI 0·80-1·12]; log-rank p=0·53). In the poor prognosis subgroup, median overall survival also did not differ between the two treatment groups (11·0 months [95% CI 9·3-13·3] in the custursin group vs 10·9 months [8·2-12·4] in the control group; HR 0·97 [95% CI 0·80-1·21]; two-sided p=0·80). The most frequently reported grade 3 or worse adverse events in the custirsen versus control groups were neutropenia (70 [22%] of 315 vs 61 [20%] of 312), anaemia (68 [22%] vs 49 [16%]), fatigue (23 [7%] vs 18 [6%]), asthenia (16 [5%] vs 8 [3%]), bone pain (16 [5%] vs 5 [2%]), and febrile neutropenia (16 [5%] vs 9 [3%]). Serious adverse events were reported in 155 (49%) versus 132 (42%). 27 patients died within 30 days of treatment in the cabazitaxel and prednisone plus custirsen group, seven of which were deemed to be treatment related, versus 17 in the cabazitaxel and prednisone group, eight of which were deemed to be treatment related. Of the 21 deaths reported, 15 were reported as complications related to study treatment, either chemotherapy (eight and three, respectively) or study drug (none and four, respectively). INTERPRETATION: We noted no survival benefit in men with metastatic castration-resistant prostate cancer with the addition of custirsen to cabazitaxel and prednisone treatment. Cabazitaxel and prednisone remains the standard of care for patients with metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy. FUNDING: OncoGenex Pharmaceuticals.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Beer TM, Hotte SJ, Saad F, et al. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Lancet Oncol. 2017. PMID: 29033099. doi:10.1016/S1470-2045(17)30605-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。